Notice2021-14702
Prospective Grant of an Exclusive Patent License: Oligonucleotides Analogues Targeting Human LMNA “lamin A” Gene
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
July 12, 2021
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Human Genome Research Institute (NHGRI), an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive, Sublicensable Patent License to consolidate co-owned rights to the inventions and the Patents and Patent Applications listed in the Supplementary Information section of this notice to The Progeria Research Foundation ("PRF"), having a place of business in 200 Lake Street, Unit 102, Peabody, MA 01960.
Full Text
<html>
<head>
<title>Federal Register, Volume 86 Issue 130 (Monday, July 12, 2021)</title>
</head>
<body><pre>
[Federal Register Volume 86, Number 130 (Monday, July 12, 2021)]
[Notices]
[Pages 36563-36564]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-14702]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License:
Oligonucleotides Analogues Targeting Human LMNA ``lamin A'' Gene
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Human Genome Research Institute (NHGRI), an
institute of the National Institutes of Health, Department of Health
and Human Services, is contemplating the grant of an Exclusive,
Sublicensable Patent License to consolidate co-owned rights to the
inventions and the Patents and Patent Applications listed in the
Supplementary Information section of this notice to The Progeria
Research Foundation (``PRF''), having a place of business in 200 Lake
Street, Unit 102, Peabody, MA 01960.
DATES: Only written comments and/or applications for a license that are
received by the NHGRI Office of Technology Transfer Office on or before
July 27, 2021 will be considered.
ADDRESSES: Requests for a copy of the patent application(s), inquiries,
and comments relating to the contemplated license should be directed
to: Eggerton Campbell, License and Patent Manager, NHGRI Technology
Transfer Office, Telephone: 301-402-1648; email:
<a href="/cdn-cgi/l/email-protection#3a5f5d5d5f484e555414595b574a585f56567a545352145d554c"><span class="__cf_email__" data-cfemail="82e7e5e5e7f0f6edecace1e3eff2e0e7eeeec2ecebeaace5edf4">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: The following and all continuing U.S. and
foreign patents/patent applications thereof are the intellectual
properties to be licensed under the prospective agreement:
----------------------------------------------------------------------------------------------------------------
Country Title Application No. Patent No.
----------------------------------------------------------------------------------------------------------------
United States........... Methods For Treating Progeroid Laminopathies 61/568,590..............
Using Oligonucleotide Analogues Targeting
Human LMNA NIH E-044-2013-0-US-01.
WIPO.................... Methods For Treating Progeroid Laminopathies PCT/US12/068609.........
Using Oligonucleotide Analogues Targeting WO 2013/086444..........
Human LMNA NIH E-044-2013-0-PCT-03.
United Kingdom.......... Methods For Treating Progeroid Laminopathies 12806796.4.............. 2788488
Using Oligonucleotide Analogues Targeting
Human LMNA NIH E-044-2013-0-GB-12.
United States........... Methods For Treating Progeroid Laminopathies 13/708,709.............. 9,326,992
Using Oligonucleotide Analogues Targeting
Human LMNA NIH E-044-2013-0-US-02.
United States........... Methods For Treating Progeroid Laminopathies 15/084,255.............. 9,833,468
Using Oligonucleotide Analogues Targeting
Human LMNA NIH E-044-2013-0-US-06.
United States........... Methods For Treating Progeroid Laminopathies 15/727,483 CON.......... 10,398,721
Using Oligonucleotide Analogues Targeting
Human LMNA NIH E-044-2013-0-US-07.
Europe.................. Methods For Treating Progeroid Laminopathies 12806796.4.............. 2788488
Using Oligonucleotide Analogues Targeting
Human LMNA NIH E-044-2013-0-EP-04.
Japan................... Methods For Treating Progeroid Laminopathies 2019-109410.............
Using Oligonucleotide Analogues Targeting
Human LMNA NIH E-044-2013-0-JP-15.
France.................. Methods For Treating Progeroid Laminopathies 12806796.4.............. 2788488
Using Oligonucleotide Analogues Targeting
Human LMNA NIH E-044-2013-0-FR-11.
Germany................. Methods For Treating Progeroid Laminopathies 12806796.4.............. 2788488
Using Oligonucleotide Analogues Targeting
Human LMNA NIH E-044-2013-0-DE-10.
Ireland................. Methods For Treating Progeroid Laminopathies 12806796.4.............. 2788488
Using Oligonucleotide Analogues Targeting
Human LMNA NIH E-044-2013-0-IE-13.
Japan................... Methods For Treating Progeroid Laminopathies 2014-546152............. 6132849
Using Oligonucleotide Analogues Targeting
Human LMNA NIH E-044-2013-0-JP-05.
Japan................... Methods For Treating Progeroid Laminopathies 2017-41744..............
Using Oligonucleotide Analogues Targeting
Human LMNA NIH E-044-2013-0-JP-08.
Netherlands............. Methods For Treating Progeroid Laminopathies 12806796.4.............. 2788488
Using Oligonucleotide Analogues Targeting
Human LMNA NIH E-044-2013-0-NL-14.
Switzerland............. Methods For Treating Progeroid Laminopathies 12806796.4.............. 2788488
Using Oligonucleotide Analogues Targeting
Human LMNA NIH E-044-2013-0-CH-09.
United States........... Oligonucleotide Analogues Targeting Human 62/330,027..............
LMNA NIH E-044-2013-1-US-01.
WIPO.................... Oligonucleotide Analogues Targeting Human PCT/US17/30174..........
LMNA NIH E-044-2013-1-PCT-02. WO 2017/190041..........
[[Page 36564]]
United States........... Oligonucleotide Analogues Targeting Human 16/096,524 (371-national 10,822,608
LMNA NIH E-044-2013-1-US-16. phase).
United States........... Oligonucleotide Analogues Targeting Human 17/024,100..............
LMNA.
Australia............... Oligonucleotide Analogues Targeting Human 2017258642..............
LMNA NIH E-044-2013-1-AU-03.
Brazil.................. Oligonucleotide Analogues Targeting Human BR1120180722790.........
LMNA NIH E-044-2013-1-BR-04.
Canada.................. Oligonucleotide Analogues Targeting Human 3,022,303...............
LMNA NIH E-044-2013-1-CA-05.
China................... Oligonucleotide Analogues Targeting Human 201780040785.7..........
LMNA NIH E-044-2013-1-CN-06.
Colombia................ Oligonucleotide Analogues Targeting Human NC2018/0012783..........
LMNA NIH E-044-2013-1-CO-07.
Eurasia................. Oligonucleotide Analogues Targeting Human 201892467...............
LMNA NIH E-044-2013-1-EA-08.
Europe.................. Oligonucleotide Analogues Targeting Human 17735676.3..............
LMNA NIH E-044-2013-1-EP-09.
Hong Kong............... Methods For Treating Progeroid Laminopathies 19126894.5..............
Using Oligonucleotide Analogues Targeting
Human LMNA NIH E-044-2013-1-HK-17.
India................... Oligonucleotide Analogues Targeting Human 201847043433............
LMNA NIH E-044-2013-1-IN-10.
Japan................... Oligonucleotide Analogues Targeting Human 2019-508165.............
LMNA NIH E-044-2013-1-JP-11.
Korea (South)........... Oligonucleotide Analogues Targeting Human 10-2018-7034615.........
LMNA NIH E-044-2013-1-KR-12.
Mexico.................. Oligonucleotide Analogues Targeting Human MX/A/2018/013157........
LMNA NIH E-044-2013-1-MX-13.
New Zealand............. Oligonucleotide Analogues Targeting Human 747685..................
LMNA NIH E-044-2013-1-NZ-14.
Singapore............... Oligonucleotide Analogues Targeting Human 11201809468X............
LMNA NIH E-044-2013-1-SG-15.
----------------------------------------------------------------------------------------------------------------
The patent rights in these inventions have been assigned to the
Government of the United States of America, the University of Maryland,
Sarepta Therapeutics, Inc, and the Progeria Research Foundation (PRF),
co-owners of said rights, for commercial development and marketing. The
rights to be granted by NHGRI are controlled by NHGRI by virtue of co-
ownership and a license received to the listed intellectual property.
The prospective patent license will be for the purpose of consolidating
the patent rights to PRF. Consolidation of these co-owned rights is
intended to expedite development of the invention, consistent with the
goals of the Bayh-Dole Act codified as 35 U.S.C. 200-212. The
prospective patent license will be worldwide, exclusive, may be limited
to those fields of use commensurate in scope with the patent rights,
and will be sublicensable.
The subject technology pertains to modified oligonucleotides
(called phosphorodiamidate morpholino oligonucleotides or PMOs)
targeted to pre-mRNA of human LMNA Lamin A gene. These PMOs can be used
to correct aberrant splicing of LMNA gene known to be involved in
Hutchinson-Gilford Progeria Syndrome (HGPS), and could be used in
treating this ultra-rare disease and related laminopathies.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective Exclusive Patent License will be royalty
bearing and may be granted unless, within fifteen (15) days from the
date of this published notice, the NHGRI Technology Transfer Office
receives written evidence and argument that establishes that the grant
of the license would not be consistent with the requirements of 35
U.S.C. 209 and 37 CFR part 404.
Complete applications for a license that are timely filed in
response to this notice will be treated as objections to this to the
grant of the contemplated exclusive patent license.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information from these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: June 29, 2021.
Claire T. Driscoll,
Director, Technology Transfer Office, National Human Genome Research
Institute, National Institutes of Health.
[FR Doc. 2021-14702 Filed 7-9-21; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on July 12, 2021.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.